Yahoo
Paris - Delayed Quote EUR

Valbiotis SA (ALVAL.PA)

0.6440 +0.0160 (+2.55%)
As of 3:09:59 PM GMT+1. Market Open.
Chart Range Bar
Loading chart for ALVAL.PA
  • Previous Close 0.6280
  • Open 0.6900
  • Bid --
  • Ask --
  • Day's Range 0.6420 - 0.6900
  • 52 Week Range 0.4860 - 1.2960
  • Volume 59,453
  • Avg. Volume 109,470
  • Market Cap (intraday) 22.855M
  • Beta (5Y Monthly) -0.19
  • PE Ratio (TTM) --
  • EPS (TTM) -0.3200
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est 1.35

Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France and Asia. The company offers supplements for immunity and vitality, health and wellbeing, metabolic and cardiovascular health, and beauty and physical comfort. It also develops TOTUM-63 for the reduction of fasting blood glucose and treatment of type 2 diabetes; TOTUM-854, which is in Phase II/III clinical trials for reducing systolic blood pressure; and TOTUM-448 for the reduction of hepatic steatosis. Additionally, the company offers e-commerce delivery service in Belgium and Luxembourg. Valbiotis SA was incorporated in 2014 and is based in Périgny, France.

www.valbiotis.com

50

Full Time Employees

December 31

Fiscal Year Ends

Packaged Foods

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .

YTD Return

ALVAL.PA
7.20%
CAC 40 (^FCHI)
1.88%

1-Year Return

ALVAL.PA
3.88%
CAC 40 (^FCHI)
1.54%

3-Year Return

ALVAL.PA
89.71%
CAC 40 (^FCHI)
13.25%

5-Year Return

ALVAL.PA
90.89%
CAC 40 (^FCHI)
15.43%

Analyst Insights

View More

Analyst Price Targets

1.30
1.35 Average
0.6440 Current
1.40 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -25.23%

  • Return on Equity (ttm)

    -67.51%

  • Revenue (ttm)

    1.34M

  • Net Income Avi to Common (ttm)

    -8.19M

  • Diluted EPS (ttm)

    -0.3200

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    11.73M

  • Total Debt/Equity (mrq)

    34.33%

  • Levered Free Cash Flow (ttm)

    -4.67M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: